OPEN ACCESS

**Saudi Journal of Oral and Dental Research**

Abbreviated Key Title: Saudi J Oral Dent Res
ISSN 2518-1300 (Print) |ISSN 2518-1297 (Online)
Scholars Middle East Publishers, Dubai, United Arab Emirates
Journal homepage: https://saudijournals.com

**Review Article**

# COVID -19 Vaccination – A Ray of Hope!!

Jagriti Yadav[1*], Pradeep Tangade[2], Ankita Jain[3], Nimisha Kumari[4]

[1]Postgraduate Student, Department of public health dentistry, Teerthanker Mahaveer Dental College & Research Centre, Moradabad, Uttar Pradesh, India
[2]Professor & H.O.D, Department of public health dentistry, Teerthanker Mahaveer Dental College & Research Centre, Moradabad, Uttar Pradesh, India
[3]Reader, Department of public health dentistry, Teerthanker Mahaveer Dental College & Research Centre, Moradabad, Uttar Pradesh, India
[4]Postgraduate Student, Department of Pedodontics and preventive, Teerthanker Mahaveer Dental College & research Center, Moradabad, Uttar pradesh, India

**DOI:** 10.36348/sjodr.2021.v06i07.003 | **Received:** 21.05.2021 | **Accepted:** 25.06.2021 | **Published:** 17.07.2021

***Corresponding author:** Jagriti Yadav

## Abstract

On January 16, 2021, Free vaccination against COVID-19 get the ball rolling in India and the government is expected to be the largest vaccination lay out in the world and pleading all of its citizens to be immunized. Four of the eight COVID-19 vaccines currently undergoing clinical trials in India were created there. Covishield (the Oxford-AstraZeneca vaccine) and Covaxin, a home-grown vaccine produced by Bharat Biotech, have been licenced for limited emergency use by India's medicines authority. Manufacturers in India have said that they will be able to meet the country's future COVID-19 vaccination needs.

**Keywords:** Covid 19, soothing vaccine.



## INTRODUCTION

A novel coronavirus (nCoV) spillover event has arisen as a public health emergency of international significance, with its epicentre in Wuhan, People's Republic of China. This outbreak began in December 2019, and as of February 28, 2020, there have been 83,704 confirmed cases of new coronavirus disease 2019 (COVID-19) worldwide, with 2,859 deaths, for a case fatality rate of 33%. India, which has a sophisticated vaccine development programme, intends to manufacture COVID-19 vaccine domestically as well as distribute it to countries that cannot afford to acquire expensive vaccines from the West. Even though some of the final details aren't known in India, data from clinical trials of many vaccinations support their eligibility for emergency permission

**In India, candidates for the COVID-19 vaccine are being tested in clinical trials.**

**Oxford–AstraZeneca COVID-19 vaccine**

A viral vector vaccine developed by the British University of Oxford, British-Swedish firm AstraZeneca, and the Coalition for Epidemic Preparedness Innovations and distributed under the brand names Vaxzevria and Covishield. Due to a tiny number of complaints of an uncommon blood clot condition, the Oxford–AstraZeneca vaccine has been permanently suspended in Denmark and Norway. Two days after receiving a vaccination, side symptoms were frequently observed. Participants were asked to fill out a survey about side effects, and 66% of them said they had experienced at least one symptom following vaccination. Tiredness (45%) was the most common, followed by myalgia (44%), fever (34%), headache (28%), local pain at the injection site (27%), and joint pain (12%) nausea (8%) and diarrhea (3%).

**Pfizer–BioNTech COVID-19 vaccine**

This vaccine, also known as Comirnaty, is an mRNA vaccine developed by BioNTech in Germany and Pfizer in the United States. Fosun Pharma distributes Comirnaty in mainland China, Hong Kong, and Macau.

The vaccine was the first COVID 19 vaccine to be approved for emergency use and the first to be cleared for routine use by a strict regulatory authority. The United Kingdom was the first country to sanction its usage in an emergency in December 2020.

COVID-19 is prevented by the Pfizer–BioNTech COVID-19 vaccine, which protects against infection with the SARS-CoV-2 virus.Severe allergic reaction is one of the side effects.Pain at the injection site (84.1 percent), fatigue (62.9 percent), headache (55.1 percent), muscle pain (38.3 percent), chills (31.9 percent), joint pain (23.6 percent), fever (14.2 percent), injection site swelling (10.5 percent), injection site redness (9.5 percent), nausea (1.1 percent), and malaise were all reported as adverse reactions in participants 16 and older in clinical studies. The COVID-19 vaccine from Pfizer BioNTech shows a 95 percent effectiveness against symptomatic SARS-CoV-2 infection.

**Johnson & Johnson COVID-19 vaccine**

Janssen Pharmaceutica (a Johnson & Johnson company) and Beth Israel Deaconess Medical Center have developed a viral vector vaccine. It's also known as COVID-19 Vaccine Janssen and Janssen COVID-19 Vaccine. Due to a possible link between the Johnson & Johnson vaccine and a rare blood clot problem, three countries, Denmark, Finland, and Norway, have stopped using it in favour of other vaccines. It is a single-dose vaccination, as opposed to two-dose COVID-19 vaccines like those made by Pfizer and Moderna. The Food and Drug Administration (FDA)Trusted Source and the European Commission, on a recommendation from the European Medicines Agency (EMA), issued emergency and conditional authorization for the Johnson & Johnson vaccine for people aged 18 and up in early 2021. In 40 countries, the vaccine has been licenced for emergency use. headaches • fever • exhaustion • muscular aches • nausea • discomfort, irritation, redness, and swelling at the injection site are all possible adverse effects.

**Sinopharm-BBIBP**

The China National Pharmaceutical Group (Sinopharm) and its Beijing Institute of Biological Products have developed BBIBP-CorV, an inactivated viral vaccine.

WHO The first and second doses should be separated by 3–4 weeks. The second dose does not need to be repeated if it is given fewer than three weeks after the first. If the second dose is not given within 4 weeks, it should be given as soon as feasible. Vaccination is one of the most significant medical breakthroughs in contemporary history . As the coronavirus disease 2019 (COVID-19) pandemic rages on, the development of an effective vaccine is critical to preventing further disease morbidity and mortality, as well as, ideally, limiting viral infection's global spread.

**Moderna COVID-19 vaccine**

- COVID-19 Vaccine is another name for this vaccine. Moderna is an mRNA vaccine developed by Moderna, the National Institute of Allergy and Infectious Diseases of the United States, the Biomedical Advanced Research and Development Authority of the United States, and the Coalition for Epidemic Preparedness Innovations.mRNA-1273 is a gene that is found in the human genome. ModernaTX, Inc. is the manufacturer. mRNA vaccine is a type of vaccine. The number of shots is two, and they are separated by 28 days. How it's Given: A shot to the upper arm muscle does not imply Eggs, preservatives, latex, and metals are all present. You should not obtain an mRNA COVID-19 vaccine if you have had a severe allergic reaction (anaphylaxis) or an acute allergic reaction, even if it was not severe, to any ingredient in an mRNA COVID-19 vaccine (such as polyethylene glycol).
- Possible Negative Consequences .In the arm where the shot was fired:• Pain• Redness• Swelling
- The rest of your body consists of:• Tiredness• Headache• Muscle ache• Chills• Fever• Nausea

Within a day or two of receiving the vaccine, these adverse effects appear. They're natural indicators that your body is preparing to defend itself, and they'll go away in a few days.

**Sputnik V COVID-19 vaccine**

The Russian Gamaleya Research Institute of Epidemiology and Microbiology developed a viral vector vaccine. Sputnik V uses two separate human adenoviruses, unlike Covishield, which uses a weakened common cold "adenovirus" that affects chimps. The first dosage of Sputnik V was provided in Hyderabad after receiving approval from the Central Drugs Laboratory, which conducted several testing on the vaccine's purity and stability

**Novanax protein based vaccine**

Codenamed NVX-CoV2373, and also called SARS-CoV-2 rS (recombinant spike) protein nanoparticle with Matrix-M1 adjuvant, is a COVID-19 vaccine candidate developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI) and is undergoing trials in India under the brand name Covovax. It requires two doses and is stable at 2 to 8 °C (36 to 46 °F) refrigerated temperatures. Novavax plans on seeking authorization for the vaccine in the U.S., Europe, and other countries by the end of September 2021, with the goal of producing 100 million doses a month by then.

**Sinovac/Coronavac inactived virus type vaccine**

Sinovac Biotech, a Chinese business, has created an inactivated viral COVID-19 vaccine. It was tested in Phase III clinical trials in Brazil, Chile, Indonesia, the Philippines, and Turkey, and it uses classic technology comparable to BBIBP-CorV and Covaxin, two other COVID-19 inactivated-virus vaccines. CoronaVac does not require freezing, and both the finished product and the raw material used to make CoronaVac can be delivered chilled at 2–8 °C (36–46 °F), the same temperature as flu vaccines.

## REFERENCE


- Kataria, S., Sharma, P., Deswal, V., Kumar, K., Singh, M. K., Alam, S., ... & Trehan, N. (2021). A Real World Evaluation of the safety and immunogenicity of the Covishield vaccine, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) in Health Care Workers (HCW) in National Capital Region (NCR) of India: A preliminary report. medRxiv.
- Gupta, R., Kumar, V. M., Tripathi, M., Datta, K., Narayana, M., Sarmah, K. R., ... & Mallick, H. N. (2020). Guidelines of the Indian Society for Sleep Research (ISSR) for practice of sleep medicine during COVID-19. Sleep and vigilance, 1-12.
- Pandi-Perumal, S. R., Gulia, K. K., Gupta, D., & Kumar, V. M. (2020). Dealing with a pandemic: the Kerala Model of containment strategy for COVID-19. Pathogens and global health, 114(5), 232-233.
- Gulia, K. K., & Kumar, V. M. (2020). Reverse quarantine in Kerala: managing the 2019 novel coronavirus in a state with a relatively large elderly population. Psychogeriatrics, 20(5), 794-795.
- Gulia, K. K., & Kumar, V. M. (2020). Importance of sleep for health and wellbeing amidst COVID-19 pandemic. Sleep Vigil, 4(1), 49-50.
- Cardinali, D. P., Brown, G. M., Reiter, R. J., & Pandi-Perumal, S. R. (2020). Elderly as a high-risk group during COVID-19 pandemic: effect of circadian misalignment, sleep dysregulation and melatonin administration. Sleep and vigilance, 1-7.
- Gupta, I., & Baru, R. (2020). Economics & ethics of the COVID-19 vaccine: how prepared are we? Indian J Med Res, 152, 153–155.
- Vignesh, R., Shankar, E. M., Vijayakumar, V., & Thyagarajan, S. P. (2020). Is Herd Immunity against SAR-CoV2 a silver lining? Front Immunol, 11, 586781.
- Le, T. T., Cramer, J. P., Chen, R., & Mayhew, S. (2020). Evolution of the COVID-19 vaccine development landscape. Nat. Rev. Drug Discov, 19, 667–668.
- Kochhar, S., & Salmon, D. A. (2020). Planning for COVID-19 vaccines safety surveillance. Vaccine, 38, 6194–6198.
- Krause, P., Fleming, T. R., Longini, I., Henao-Restrepo, A. M., & Peto, R. (2020). World Health Organization Solidarity Vaccines Trial Expert Group. COVID-19 vaccine trials should seek worthwhile efficacy. Lancet, 396, 741–743.
- Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., ... & Zhu, F. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet infectious diseases, 21(2), 181-192.
- Bar-Zeev, N., & Kochhar S. (2020). Expecting the unexpected with COVID-19 vaccines. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(20)30870-7.
- Vaccine information, ICMR New Delhi—COVID-19 vaccine. https://vaccine.icmr.org.in/covid-19-vaccine (2021).
- Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., ... & Bijker, E. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397(10269), 99-111.
- Keech, C., Albert, G., Cho, I., Robertson, A., Reed, P., Neal, S., ... & Glenn, G. M. (2020). Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. New England Journal of Medicine, 383(24), 2320-2332.
- Liu, Y., Wang, K., Massoud, T. F., & Paulmurugan, R. (2020). SARS-CoV-2 vaccine development: an overview and perspectives. ACS Pharm Transl Sci, 3, 844–858.
- Ella, R., Vadrevu, K. M., Jogdand, H., Prasad, S., Reddy, S., Sarangi, V., ... & Bhargava, B. (2021). Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. The Lancet Infectious Diseases, 21(5), 637-646.
- Logunov, D. Y., Dolzhikova, I. V., Zubkova, O. V., Tukhvatullin, A. I., Shcheblyakov, D. V., Dzharullaeva, A. S., ... & Gintsburg, A. L. (2020). Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet, 396(10255), 887-897.
- Johns Hopkins University Coronavirus Resource Center. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. 2020 (https://coronavirus.jhu.edu/map.html. opens in new tab)
- World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 — 11 March 2020 (https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. opens in new tab).
- Centers for Disease Control and Prevention. COVID-19 information page (https://www.cdc.gov/coronavirus/2019-ncov/index.html. opens in new tab).
- Walsh, E. E., Frenck Jr, R. W., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., ... & Gruber, W. C. (2020). Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine, 383(25), 2439-2450.
- Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., ... & Weissman, D. (2015). Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. Journal of Controlled Release, 217, 345-351.
- Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008). Incorporation of pseudouridine into mRNA yields

superior nonimmunogenic vector with increased translational capacity and biological stability. Molecular therapy, 16(11), 1833-1840.

- Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C. L., Abiona, O., ... & McLellan, J. S. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 367(6483), 1260-1263.
- Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., ... & Türeci, Ö. (2020). BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. MedRxiv.
- Food and Drug Administration. Guidance for industry: emergency use authorization for vaccines to prevent COVID-19. October 2020 (https://www.fda.gov/media/142749/download. opens in new tab).
- Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., ... & Lessler, J. (2020). The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Annals of internal medicine, 172(9), 577-582.
- Cowling, B. J., Perera, R. A., Valkenburg, S. A., Leung, N. H., Iuliano, A. D., Tam, Y. H., ... & Thompson, M. G. (2020). Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clinical Infectious Diseases, 71(7), 1704-1714.
- Centers for Disease Control Prevention. (2011). Ten great public health achievements—United States, 2001–2010. MMWR Morb. Mortal. Wkly Rep, 60, 619.
- Gavi. The Gavi COVAX AMC: An Investment Opportunity. Available online: http://www.gavi.org/covax-facility (accessed on 30 December 2020).
- World Health Organization. (2021). Draft Landscape of COVID-19 Candidate Vaccines. Available online: http://www.dropbox.com/s/ jiqqdl96g7qf3f1/20210106-NovelCoronavirus_Landscape_COVID.xlsx?dl=0 (accessed on 7 January 2021).
- Le, T. T., Cramer, J. P., Chen, R., & Mayhew, S. (2020). Evolution of the COVID-19 vaccine development landscape. Nat Rev Drug Discov, 19(10), 667-668.
- NCT04683224. A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine. Available online: https://clinicaltrials.gov/ct2/show/NCT04683224 (accessed on 6 January 2021).
- NCT04642638. Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Healthy Seronegative Adults at High Risk of SARS-CoV-2 Exposure. Available online: https://clinicaltrials.gov/ct2/show/NCT04642638 (accessed on 7 January 2021). Vaccines 2021, 9, 227 15 of 18
- INOVIO. Pharmaceuticals INOVIO and Advaccine Announce First Dosing of Subject in Phase 2 Clinical Trial for COVID-19 DNA Vaccine Candidate INO-4800 in China. Available online: http://ir.inovio.com/news-releases/news-releases-details/ 2020/INOVIO-and-Advaccine-Announce-First-Dosing-of-Subject-in-Phase-2-Clinical-Trial-for-COVID-19-DNA-VaccineCandidate-INO-4800-in-China/default.aspx (accessed on 7 January 2021).
- Reuters. Japan's AnGes Begins Phase 2/3 Clinical Trial of DNA-Based COVID-19 Vaccine. Available online: http: //www.reuters.com/article/us-anges-covid-vaccine/japans-anges-begins-phase-2-3-clinical-trial-of-dna-based-covid19-vaccine-idINKBN28I0EA (accessed on 7 January 2021).
- NCT04672395. A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (SCB-2019).
- Astra, Z. (2020). AstraZeneca's COVID-19 Vaccine Authorised for Emergency Supply in the UK. Available online: http://www. astrazeneca.com/media-centre/press-releases/2020/astrazenecas-covid-19-vaccine-authorised-in-uk.html (accessed on 30 December 2020).
- Oliver, S. E. (2020). The advisory committee on immunization practices' interim recommendation for use of moderna COVID-19 vaccine—United States, December 2020. MMWR. Morbidity and mortality weekly report, 69, 1653-1656.
- McNeil, M. M., & DeStefano, F. (2018). Vaccine-associated hypersensitivity. Journal of Allergy and Clinical Immunology, 141(2), 463-472.
- CDC. COVID-19 vaccination: clinical considerations. Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States. Atlanta, GA: US Department of Health and Human Services, CDC; 2020.
- CDC. COVID-19 vaccination: clinical considerations. Interim considerations: preparing for the potential management of anaphylaxis after COVID-19 vaccination. Atlanta, GA: US Department of Health and Human Services, CDC; 2020.
- COVID, C. (2021). Response TeamFood and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine—United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep, 70(2), 46-51.
- Shimabukuro, T. T., Nguyen, M., Martin, D., & DeStefano, F. (2015). Safety monitoring in the vaccine adverse event reporting system (VAERS). Vaccine, 33(36), 4398-4405.
- Covovax trials begin in India, launch hopefully in September: Adar Poonawalla". India Today. 27 March 2021. Retrieved 28 March 2021.